Contribution: Industrial Research Assistance Program – Contributions to Firms
Hexiris Inc.
$75,000.00
Implant Stability and Performance Studies
FY 2022-23 · 2022-10-17
Summary
The next generation of implant and delivery system for ab-external minimally invasive glaucoma surgery (MIGS) which will enable bringing glaucoma surgery from the operating room to outpatient clinics.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Dieppe|Dieppe, New Brunswick, Canada
Recipient Type
For-profit organization
Business Number
766125470
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-10-17 | 2022-23 | $75,000.00 |
| 1 | 2022-10-17 | 2022-23 | $75,000.00 |
| 2 | 2022-10-17 | 2022-23 | $75,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2023-12-31
Agreement Number
996212
Agreement Start Date
2022-10-17
Agreement Title
Implant Stability and Performance Studies
Agreement Title (French)
Études sur la stabilité et les performances des implants
Agreement Type
Contribution
Agreement Value
$75,000.00
Amendment Date
2023-09-20
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The next generation of implant and delivery system for ab-external minimally invasive glaucoma surgery (MIGS) which will enable bringing glaucoma surgery from the operating room to outpatient clinics.
Description (French)
La prochaine génération d’implant et de système d’administration pour la chirurgie ab-externe mini-invasive du glaucome (MIGS) qui permettra de faire passer la chirurgie du glaucome de la salle d’opération aux cliniques externes.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Beauséjour
Federal Riding (French)
Beauséjour
Federal Riding Number
13002
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
766125470
Recipient City
Dieppe|Dieppe
Recipient Country
CA
Recipient Legal Name
Hexiris Inc.
Recipient Postal Code
E1A 7R8
Recipient Province or Territory
NB
Recipient Type
F
Reference Number
172-2022-2023-Q3-996212
